title: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients.
abstract: Four Chinese patients with non-Hodgkin's lymphoma and asymptomatic chronic hepatitis B infection developed fulminant hepatitis three to four weeks after two to five courses of chemotherapy. One was initially positive for hepatitis B e antigen and three were positive for antibody to HBeAg. They had normal initial serum aminotransferase levels. In all four patients, the hepatic illness appeared to be caused by reactivation of hepatitis B virus replication as evidenced by the appearance of HBV DNA in serum at the onset of hepatitis, seroreversion from anti-HBe to HBeAg positivity, and the absence of other incriminating drugs or viral markers. All died within three weeks after the onset of jaundice. Serum HBV DNA level dropped to undetectable level as the hepatitis progressed. We postulate that potent cytotoxic therapy reactivated HBV replication and permitted widespread infection of hepatocytes. Upon withdrawal of chemotherapy, the immunologic rebound resulted in rapid destruction of infected hepatocytes and massive liver necrosis. Several methods for the prevention of such hepatic reactivation are discussed.
authors.affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong.
authors.forename: J Y
authors.initials: JY
authors.lastname: Lau
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: H J
authors.initials: HJ
authors.lastname: Lin
authors.forename: A S
authors.initials: AS
authors.lastname: Lok
authors.forename: R H
authors.initials: RH
authors.lastname: Liang
authors.forename: P C
authors.initials: PC
authors.lastname: Wu
authors.forename: T K
authors.initials: TK
authors.lastname: Chan
authors.forename: D
authors.initials: D
authors.lastname: Todd
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002353:Carrier State; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced* / Q000382:microbiology / Q000401:mortality; D006514:Hepatitis B Surface Antigens / Q000302:isolation & purification; D006513:Hepatitis B e Antigens / Q000302:isolation & purification; D006801:Humans; D008099:Liver / Q000382:microbiology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013375:Substance Withdrawal Syndrome; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens